Roche takes on Loxo, Bayer in gene-defined cancer class
October 21, 2018 at 05:12 AM EDT
Roche's entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.